Latest
Research, clinical trials, regulatory updates, and industry analysis from the longevity medicine world.
A UC Berkeley study found that combining oxytocin with an Alk5 inhibitor extended lifespan by 70% in frail elderly male mice. Benefits were sex-specific — females showed no lasting improvement. Here's what the data says and whether it could reach humans.
UT Health San Antonio launches a National Institute on Aging-funded rapamycin trial with 84 older adults—one of the largest longevity-focused clinical studies to date. The shift: from off-label speculation to evidence-based dosing.
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.
A new franchise concept of 'longevity studios' blends recovery therapies (red light, HBOT, cold plunge) with clinical upsells (biomarkers, NAD, GLP-1, HRT, peptides, IV).